NeuraLight Reaches Key Milestone with Completion of International Multicenter Parkinson’s Clinical Trial
PALOMA study is one of the largest longitudinal studies using eye movement biomarkers in patients with Parkinson’s disease
The original version of this press release is available on Business Wire
NEW YORK & TEL AVIV, Israel–(BUSINESS WIRE)–NeuraLight,the leader in developing precision biomarkers for neurology, today announced the completion of PALOMA, a pioneering study comparing eye-movement measures with standard clinical Parkinson’s assessments. The 12-month, multi-center longitudinal study had a cohort of 300 participants across multiple clinical sites, making it one of the largest longitudinal clinical trials using eye-movement biomarkers to follow disease progression in patients with Parkinson’s over time.
PALOMA (Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson’s Disease) focused on the use of eye-movement based biomarkers to monitor disease progression in comparison with standard, widely used clinical assessments. The study used NeuraLight’s software-based platform to evaluate the status of patients with idiopathic Parkinson’s disease, alongside standard neurological assessments such as MDS-UPDRS and MoCA.
“PALOMA is an important step toward more objective, scalable ways to track Parkinson’s disease progression in real-world clinical research. By comparing NeuraLight’s precise eye-movement measures with standard clinical outcome assessments (COAs), such as MDS-UPDRS and MoCA, we can capture consistent signs of change over time,” said Dr. Michelle Tosin, leading principal investigator of the trial and head assistant professor in the Department of Neurological Sciences at Rush University Medical Center in Chicago. “The NeuraLight platform is also user-friendly and practical to deploy. In our experience, patients tolerate the examination well, which supports repeat use over time and makes this approach well-suited for multicenter studies. These results suggest NeuraLight’s oculometric biomarkers can help measure progression in clinical trials with greater sensitivity and repeatability.”
A paper detailing the study’s full results is currently under review in a leading peer-reviewed journal. Initial PALOMA data presented by Dr. Tosin at the 2024 MDS International Congress, demonstrated that NeuraLight’s eye-movement biomarkers correlate with clinical scores in Parkinson’s disease.
The PALOMA Trial was conducted across international academic centers, including leading clinical centers in the US, Portugal, Spain and the UK.
“This international study provides further evidence of NeuraLight’s ability to deliver precision neurology biomarkers that bring unprecedented sensitivity to neurological assessment,” said Edmund Ben-Ami, NeuraLight’s CEO and co-founder. “For the first time, a biomarker has outperformed the neurological gold standard in tracking Parkinson’s disease over time, unlocking a new standard in neurology.”
The NeuraLight platform can deliver biomarkers with 10x more sensitivity than MDS-UPDRS, the current gold standard for measuring Parkinson’s progression. The platform is currently deployed in clinical partnerships across the globe, spanning over thousands of patients with Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA) and Huntington’s disease, as well as in multiple commercial pharmaceutical trials.
The completion of the PALOMA study comes on the heels of NeuraLight’s announcement of its Scientific Advisory Board members, which include multiple globally recognized scientific leaders and Nobel laureates.
About PALOMA
PALOMA (NCT05862649)is a multi-center longitudinal study that enrolled approximately 300 patients with idiopathic Parkinson’s disease (Hoehn & Yahr 1–2; 0–5 years since diagnosis). The study evaluated correlations between oculometric measures and clinical assessments such as MDS-UPDRS and MoCA over 12 months, with the aim of assessing whether oculometric measures can detect deterioration earlier than currently available clinical tools. Learn more at ClinicalTrials.gov.